Toxic rise of clozapine plasma concentrations in relation to inflammation

European Neuropsychopharmacology

Volumn 13, Issue 5, 2003, Pages 381-385

  Haack, Marie Jeanne ^a,b   Bak, M L F J ^a,b   Beurskens, Rob ^b   Maes, Michael ^c   Stolk, L M L ^c   Delespaul, Philippe A E G ^b,d  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Psychiatric Hospital Vijverdal   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Clozapine; Cytokines; Infection; Inflammation; P450 metabolism; Toxic

Indexed keywords

AMOXICILLIN; ANTIINFLAMMATORY AGENT; BIPERIDEN; CLAVULANIC ACID; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOKINE; ETHINYLESTRADIOL; FLUOXETINE; HAPTEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LACTULOSE; LEVONORGESTREL; LEVOTHYROXINE; NORCLOZAPINE; OXAZEPAM; OXYBUTYNIN; PARACETAMOL; PROMETHAZINE; SUCRALFATE; TEMAZEPAM; VALPROIC ACID;

ADULT; ANAMNESIS; APOPTOSIS; ARTICLE; BLOOD TOXICITY; CASE REPORT; CHRONIC DRUG ADMINISTRATION; CLINICAL FEATURE; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGITIS; FEMALE; GASTROINTESTINAL INFECTION; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOMODULATION; IMMUNOREACTIVITY; INFLAMMATION; LABORATORY TEST; MALE; METABOLITE; OUTCOMES RESEARCH; PHYSICAL EXAMINATION; PNEUMONIA; PRIORITY JOURNAL; PROTEIN METABOLISM; THORAX RADIOGRAPHY; VIRUS INFECTION;

EID: 0041882102     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(03)00042-7     Document Type: Article

References (48)

1. Meltzer H.Y. Outcome in schizophrenia: beyond symptom reduction. J. Clin. Psychiatry. 60:(Suppl. 3):1999;3-7.
2. Kane J., Honigfeld G., Singer J., Melzer H. Clozapine for the treatment-resistant schizophrenic. Arch. Gen. Psychiatry. 45:1988;789-796.
3. Meltzer H.Y. Treatment-resistant schizophrenia - the role of clozapine. Curr. Med. Res. Opin. 14:(1):1997;1-20.
4. Safferman A., Lieberman J., Kan J., Szymanski S., Kinon B. Update on clinical efficacy and side-effects of clozapine. Schizophr. Bull. 17:1991;247-2628.
5. Melzer et al. submitted for publication in Archives of General Psychiatry, 2002.
6. Krupp P., Barnes P. Clozapine-associated agranulocytosis: risks and aetiology. Br. J. Psychiatry. 17:(Suppl.):1992;38-40.
7. Miller D.D. Review and management of clozapine side effects. J. Clin. Psychiatry. 61:(Suppl. 8):2000;14-17.
8. Guitton C., Abbar M., Kinowski J.M., Chabrand P., Bressolle F. Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. J. Clin. Psychopharmacol. 18:(6):1998;470-476.
9. Byerly M.J., DeVane C.L. Pharmacokinetics of clozapine and risperidone: a review of recent literature. J. Clin. Psychopharmacol. 16:1996;177-179.
10. Eiermann B., Engel G., Johansson I., Zanger U.M., Bertilsson L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br. J. Clin. Pharmacol. 44:(10):1997;439-446.
11. Schaber G., Stevens I., Gaertner H.J., Dietz K., Breyer-Pfaff U. Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. Br. J. Clin. Pharmacol. 46:(5):1998;453-459.
12. Carrillo J.A., Herraiz A.G., Ramos S.I., Benitez J. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J. Clin. Psychopharmacol. 18/4:1998;311-316.
13. Guitton C., Kinowski J.M., Abbar M., Chabrand P., Bressolle F. Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia. J. Clin. Pharmacol. 39:1999;721-728.
14. Kurz M., Hummer M., Kemmler G., Kurzthaler I., Saria A., Fleischhacker W.W. Long-term pharmacokinetics of clozapine. Br. J. Psychiatry. 173:1998;341-344.
15. Olesen O.V. Therapeutic drug monitoring of clozapine treatment. Therapeutic threshold value for serum clozapine concentrations. Clin. Pharmacokinet. 34:(6):1998;497-502.
16. Perry P.J. Therapeutic drug monitoring of atypical antipsychotics. CNS Drugs. 13:(3):2000;167-171.
17. Spina E., Avenoso A., Facciola G., Scordo M.G., Ancione M., Madia A.G., Ventimiglia A., Perucca E. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berl.). 148:(1):2000;83-89.
18. Hummer M., Kurz M., Kurzthaler I., Oberbauer H., Miller C., Fleischhacker W.W. Hepatotoxicity of clozapine. J. Clin. Psychopharmacol. 17:(4):1997;314-317.
19. Rechlin T., Beck G., Weis M., Kaschka W.P. Correlation between plasma clozapine concentration and heart rate variability in schizophrenic patients. Psychopharmacology (Berl.). 135:(4):1998;338-341.
20. Haring C., Neudorfer C., Schwitzer I., Hummer M., Saria A., Hinterhuber H., Fleischhacker W.W. EEG alterations in patients treated with clozapine in relation to plasma levels. Psychopharmacology (Berl.). 114:(1):1994;97-100.
21. Cooper T.B. Clozapine plasma level monitoring: current status. Psychiatr. Q. 67:(4):1996;297-311.
22. Raaska K., Raitasuo V., Arstila M., Neuvonen P.J. Bacterial pneumonia can increase serum concentration of clozapine. Eur. J. Clin. Pharmacol. 58:(5):2002;321-322.
23. Raaska K., Raitasuo V., Neuvonen P.J. Effect of influenza vaccination on serum clozapine and its main metabolite concentrations in patients with schizophrenia. Eur. J. Clin. Pharmacol. 57:(10):2001;705-708.
24. Cohen L.G., Chesley S., Eugenio L., Flood J.G., Fisch J., Goff D.C. Erythromycin-induced clozapine toxic reaction. Arch. Intern. Med. 156:(6):1996;675-677.
25. Funderburg L.G., Vertrees J.E., True J.E., Miller A.L. Seizures following addition of erythromycin to clozapine treatment. Am. J. Psychiatry. 151:1994;1840-1841.
26. Van der Molen-Eijgenraam M., Blanken-Meijs J.T., Heeringa M., van Grootheest A.C. Delirium due to increase in clozapine level during an inflammatory reaction. Ned. Tijdschr. Geneeskd. 145:(9):2001;427-430.
27. Bradley, Mc Cluskey, 1997. Clinical Immunology chapter 11, Drug allergy and reactions. Ed. Oxford University Press.
28. Pisciotta A.V., Konings S.A. 51Cr release assay of clozapine-induced cytotoxicity: evidence for immunogenic mechanism. J. Clin. Psychiatry. 55:(Suppl. B):1994;143-148.
29. Uetrecht J. Drug metabolism by leukocytes and its role in drug-induced lupus and other idiosyncratic drug reactions. Crit. Rev. Toxicol. 20:(4):1990;213-235. Review.
30. Williams D.P., Pirmohamed M., Naisbitt D.J., Uetrecht J.P., Park B.K. Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. Mol. Pharmacol. 58:(1):2000;207-216.
31. Pirmohamed, M., Williams, D., Madden, S., Templeton, E., Park, B.K. Metabolism and bioactivation of clozapine by human liver in vitro. Fischer, V., Haar, J.A., Greiner, L., Lloyd, R.V., Mason, R.P.
32. Liu Z.C., Uetrecht J.P. Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. J. Pharmacol. Exp. Ther. 275:(3):1995;1476-1483.
33. Uetrecht J.P. The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions. Drug. Metab. Rev. 24:(3):1992;299-366. Review.
34. Elias T.J., Bannister K.M., Clarkson A.R., Faull D., Faull R.J. Clozapine-induced acute interstitial nephritis. Lancet. 354:(9185):1999;1180-1181.
35. Killian J.G., Kerr K., Lawrence C., Celermajer D.S. Myocarditis and cardiomyopathy associated with clozapine. Lancet. 354:(9193):1999;1841-1845.
36. Wooltorton E. Antipsychotic clozapine (clozaril): myocarditis and cardiovascular toxicity. CMAJ. 166:(9):2002;1185-1186.
37. Maes M., Meltzer H.Y., Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr. Scand. 89:(5):1994;346-351.
38. Maes M., Bosmans E., Kenis G., De Jong R., Smith R.S., Meltzer H.Y. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr. Res. 26:(2-3):1997;221-225.
39. Haack M., Hinze-Selch D., Fenzel T., Kraus T., Kuhn M., Schuld A., Pollmacher T. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J. Psychiatr. Res. 33:(5):1999;407.
40. Pollmacher T., Haack M., Schuld A., Kraus T., Hinze-Selch D. Effects of antipsychotic drugs on cytokine networks. J. Psychiatr. Res. 34:(6):2000;369-382. Review.
41. Pollmacher T., Hinze-Selch D., Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J. Clin. Psychopharmacol. 16:(5):1996;403-409.
42. Pollmacher T., Fenzel T., Mullington J., Hinze-Selch D. The influence of clozapine treatment on plasma granulocyte colony-stimulating (G-CSF) levels. Pharmacopsychiatry. 30:(4):1997;118-121.
43. Iber H., Sewer M.B., Barclay T.B., Mitchell S.R., Li T., Morgan E.T. Modulation of drug metabolism in infectious and inflammatory diseases. Drug Metab. Rev. 31:(1):1999;29-41.
44. Morgan E.T. Regulation of cytochromes P450 during inflammation and infection. Drug Metab. Rev. 29:(4):1997;1129-1188.
45. Williams J.F. Cytochrome P450 isoforms. Regulation during infection, inflammation and by cytokines. J. Fla. Med. Assoc. 78:(8):1991;517-519.
46. Shedlofsky S.I., Israel B.C., McClain C.J., Hill D.B., Blouin R.A. Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J. Clin. Invest. 94:(6):1994;2209-2214.
47. Shedlofsky S.I., Israel B.C., Tosheva R., Blouin R.A. Endotoxin depresses hepatic cytochrome P450-mediated drug metabolism in women. Br. J. Clin. Pharmacol. 43:(6):1997;627-632.
48. Volpicelli S.A., Centorrino F., Puopolo P.R., Kando J., Frankenburg F.R., Baldessarini R.J., Flood J.G. Determination of clozapine, norclozapine, and clozapine-N-oxide in serum by liquid chromatography. Clin. Chem. 39:(8):1993;1656-1659.